Yazar "Çağlayan, Ahmet Burak" seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • Küçük Resim Yok
    Öğe
    Effects of peripheral ırisin ınfusion on the glucose uptake in high-fat-diet-ınduced obese rats
    (Acta physıologıca, 2018) Sandal, Süleyman; Tekin, Suat; Erden, Yavuz; Çağlayan, Ahmet Burak; Özyalin, Fatma; Cigremis, Yılmaz; Çolak, Cemil
  • Küçük Resim
    Öğe
    Schiff base poloxamer P85 combination prevents prostate cancer progression in C57 Bl6 mice
    (Prostate, 2016) Doğan, Ayşegül; Demirci, Selami; Başak, Neşe; Çağlayan, Ahmet Burak; Aydın, Safa; Telci, Dilek; Kılıç, Ertuğrul; Şahin, Kazım; Orhan, Cemal; Tuzcu, Mehmet; Şahin, Fikrettin; Doğan Ekinci, Işın Asiye
    BACKGROUND. Prostate cancer which is the second most common cause of death among men has a high incidence in recent years. Current therapeutic regimens should be improved to overcome drug resistance. At the metastatic stage, tumors become refractory to established chemotherapeutic treatments and cause serious problems at the clinics. Development of new drug molecules that are able to transport through the membrane easily and kill tumor cells rapidly is of great interest. METHOD. In the current study, a novel Heterodinuclear copper(II)Mn(II) Schiff base complex combined with P85 was used for prostate cancer treatment in vivo. Tramp-C1 cells injected animals were subjected to chemotherapeutic formulation treatment and results were analyzed by toxicology analysis, tumor volume measurements, and histopathological analysis. 0.5 mg/kg Schiff base was selected and combined with 0.05% P85 according to the toxicology analysis showing the enzyme levels, blood parameters, and multiple organ toxicity. RESULTS. Results demonstrated that Heterodinuclear copper(II)Mn(II) complex-P85 combination decreased tumor formation and tumor volume steadily over the course of experiments. CONCLUSIONS. Overall, Heterodinuclear copper(II)Mn(II) complex-P85 exerted remarkable anti-cancer activity in vivo in C57/B16 mice. Prostate 76:1454–1463, 2016. # 2016 Wiley Periodicals, Inc.
  • Küçük Resim
    Öğe
    Sensitization of cervical cancer cells to cisplatin by genistein the role of NF B and akt mTOR signaling pathways
    (Journal of Oncology Volume, 2012) Şahin, Kazım; Tuzcu, Mehmet; Başak, Neşe; Çağlayan, Ahmet Burak; Kılıç, Ertuğrul; Şahin, Fikrettin; Küçük, Ömer
    Cervical cancer is among the top causes of death from cancer in women. Cisplatin-based chemotherapy has been shown to improve survival; however, cisplatin treatment is associated with toxicity to healthy cells. Genistein has been used as an adjunct to chemotherapy to enhance the activity of chemotherapeutic agents without causing increased toxicity. The present study was designed to investigate the effect of genistein (25 μM) on antitumor activity of cisplatin (250 nM) on HeLa cervical cancer cells. We have examined the alterations in expression of NF-B, p-mTOR, p-p70S6K1, p-4E-BP1, and p-Akt protein levels in response to treatment. The combination of 25 μM genistein with 250 nM cisplatin resulted in significantly greater growth inhibition (). Genistein enhanced the antitumor activity of cisplatin and reduced the expression of NF-B, p-mTOR, p-p70S6K1, p-4E-BP1, and p-Akt. The results in the present study suggest that genistein could enhance the activity of cisplatin via inhibition of NF-κB and Akt/mTOR pathways. Genistein is a promising nontoxic nutritional agent that may enhance treatment outcome in cervical cancer patients when given concomitantly with cisplatin. Clinical trials of genistein and cisplatin combination are warranted to test this hypothesis.